Dr. Elise F. Nassif
Claim this profileM D Anderson Cancer Center
Area of expertise
Soft Tissue Sarcoma
Elise F. Nassif has run 4 trials for Soft Tissue Sarcoma. Some of their research focus areas include:
Leiomyosarcoma
Elise F. Nassif has run 4 trials for Leiomyosarcoma. Some of their research focus areas include:
Affiliated Hospitals
M D Anderson Cancer Center
University Of Texas MD Anderson Cancer Center LAO
Clinical Trials Elise F. Nassif is currently running
Abemaciclib + Gemcitabine
for Soft Tissue Sarcoma
This phase I/II trial tests the side effects and best dose of abemaciclib when added to gemcitabine and compares the effectiveness of that treatment to the usual treatment of gemcitabine with docetaxel for the treatment of patients with soft tissue sarcoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic) (phase 1) or patients with leiomyosarcoma or dedifferentiated liposarcoma (phase 2). Abemaciclib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals tumor cells to multiply. This helps slow or stop the spread of tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making deoxyribonucleic acid and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Giving abemaciclib with gemcitabine may be safe and effective when compared to treatment with gemcitabine and docetaxel for patients with advanced or metastatic soft tissue sarcoma or leiomyosarcoma or dedifferentiated liposarcoma.
Recruiting
1 award
Phase 1 & 2
5 criteria
Low-Dose Chemotherapy + Anti-Cancer Drug
for Sarcoma
This phase I trial tests the safety, side effects, and best dose of combination therapy with liposomal doxorubicin and peposertib in treating patients with sarcoma that has spread from where it first started, to other places in the body (metastatic), or cannot be removed by surgery (unresectable) and for which no known cure is available (advanced). Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It also blocks a certain enzyme needed for cell division and DNA repair. Liposomal doxorubicin is a form of the anticancer drug doxorubicin that is contained inside very tiny, fat-like particles. Liposomal doxorubicin may have fewer side effects and work better than other forms of the drug. Peposertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It may also enhance the activity of chemo- and radiotherapy. There is some pre-clinical evidence in animal models that combining peposertib with liposomal doxorubicin can shrink or stabilize certain types of cancer for longer than either drug alone, but it is not known if this will happen in people. Combination therapy with liposomal doxorubicin and peposertib may be effective in treating patients with advanced sarcoma.
Recruiting
1 award
Phase 1
More about Elise F. Nassif
Clinical Trial Related
2 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Elise F. Nassif has experience with
- Gemcitabine
- Nab-Sirolimus
- Cabozantinib
- Ipilimumab, Nivolumab
- Pegylated Liposomal Doxorubicin Hydrochloride
- Peposertib
Breakdown of trials Elise F. Nassif has run
Soft Tissue Sarcoma
Leiomyosarcoma
Uterine Leiomyosarcoma
Liposarcoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Elise F. Nassif specialize in?
Elise F. Nassif focuses on Soft Tissue Sarcoma and Leiomyosarcoma. In particular, much of their work with Soft Tissue Sarcoma has involved Stage IV patients, or patients who are TSC2 positive.
Is Elise F. Nassif currently recruiting for clinical trials?
Yes, Elise F. Nassif is currently recruiting for 2 clinical trials in Houston Texas. If you're interested in participating, you should apply.
Are there any treatments that Elise F. Nassif has studied deeply?
Yes, Elise F. Nassif has studied treatments such as Gemcitabine, Nab-Sirolimus, Cabozantinib.
What is the best way to schedule an appointment with Elise F. Nassif?
Apply for one of the trials that Elise F. Nassif is conducting.
What is the office address of Elise F. Nassif?
The office of Elise F. Nassif is located at: M D Anderson Cancer Center, Houston, Texas 77030 United States. This is the address for their practice at the M D Anderson Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.